NCT04862676CompletedEarly phase 1
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
A Pilot Study to Determine the Safety and Efficacy of Repeated Hyperbaric Oxygen Therapy in Multiple Myeloma Patients Undergoing High-Dose Therapy and Autologous Stem/Progenitor Transplantation
Source: ClinicalTrials.gov · Last updated 10 Sept 2025
Brief summary (registry, in English)
Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at WCI will be enrolled in the study.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- First submitted
- 6 Nov 2020
- Start date
- 22 Apr 2022
- Primary completion date
- 4 Apr 2025
- Lead sponsor
- University of Rochester
- Diseases
- Multiple myeloma
- NCT number
- NCT04862676
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 29
- From 22 Apr 2022 to the primary completion date, 4 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Sinus surgery within the last 5 years
- Evidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60 days of transplant
- Prior chest surgery involving thoracotomy or prior direct irradiation to the lungs
- Subjects who have had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen
- Use of tobacco 72 hours prior to transplant
Other illness
- Severe chronic obstructive pulmonary disease requiring oxygen supplementation
- History of spontaneous pneumothorax
- Active ear/sinus infection
- History of recurrent seizures within 5 years of study enrollment
- Active and uncontrolled viral, fungal or bacterial infection
Other
- Pregnant or breastfeeding
- Claustrophobia
Who the study is looking for
- Subjects with Multiple myeloma
- Subjects must be 18 years old
- Karnosfsky Performance of greater than 70 percent
- Adequate hepatic, cardiac and pulmonary function
- Subjects should have New York Heart Association Functional Classification of: Class 1 or Class II.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| James P. Wilmot Cancer Center at University of Rochester Medical Center Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.